$TVTX News

Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target

HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $67

Travere Therapeutics, Inc. (TVTX) Discusses Exclusive Licensing and Collaboration Agreement for Seborbrutinib with Everest Medicines Transcript

Travere Therapeutics Enters Into Exclusive Licensing And Collaboration Agreement With Everest Medicines For Development And Commercialization Of Civorebrutinib

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics Receives Notice Of Allowance From U.S. Patent And Trademark Office For Patent Titled Biphenyl Sulfonamide Compounds For The Treatment Of Kidney Diseases Or Disorders

Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters

Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $50

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

Travere Therapeutics Plans To Offer $400M Senior Convertible Notes Due 2032

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $60

Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $59

Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $55

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript